FDA Layoffs Could Compromise Safety of Medications Made at Foreign Factories, Inspectors Say
Beyond staff cuts, the departures of some longtime investigators in recent months have left less experienced people tasked with rooting out dangerous manufacturing practices.
Seven Things to Know About ProPublica’s Investigation of the FDA’s Secret Gamble on Generic Drugs
ProPublica spent 14 months investigating the FDA’s oversight of foreign drugmakers that send medications to the U.S. These are the key takeaways.
Threat in Your Medicine Cabinet: The FDA’s Gamble on America’s Drugs
A ProPublica investigation found that for more than a decade, the FDA gave substandard factories banned from the United States a special pass to keep sending drugs to an unsuspecting public.
We Spent a Year Investigating How the FDA Let Risky Drugs Into the U.S. Market
Our investigation exposed a little-known practice inside the FDA that allowed more than 150 drugs or their ingredients into the U.S. over the past dozen years even though they were made at factories banned from shipping their products here.
Senators Demand Transparency on Canceled Veterans Affairs Contracts
Following a ProPublica investigation into how DOGE had developed an error-prone AI tool to determine which VA contracts should be killed, a trio of lawmakers said the Trump administration continues to “stonewall” their requests for details.
Inside the AI Prompts DOGE Used to “Munch” Contracts Related to Veterans’ Health
Experts who reviewed the code for ProPublica found numerous and troubling flaws in the system, providing a disturbing glimpse into how the Trump administration is allowing artificial intelligence to guide critical cuts in services.
DOGE Developed Error-Prone AI Tool to “Munch” Veterans Affairs Contracts
We obtained records showing how a Department of Government Efficiency staffer with no medical experience used artificial intelligence to identify which VA contracts to kill. “AI is absolutely the wrong tool for this,” one expert said.
More Than a Dozen U.S. Officials Sold Stocks Before Trump’s Tariffs Sent the Market Plunging
Records show well-timed trades by executive branch employees and congressional aides. Even if they had no insider information, ethics experts say such trading undermines faith in government and the markets.
Transportation Secretary Sean Duffy Sold Stocks Two Days Before Trump Announced a Plan for Reciprocal Tariffs
Duffy is the second member of Trump’s Cabinet who sold securities shortly before the president’s tariff announcements sent markets plunging. A spokesperson for Duffy said an account manager made the trades and that Duffy had no input on the timing.
U.S. AG Pam Bondi Sold More than $1 Million in Trump Media Stock the Day Trump Announced Sweeping Tariffs
Disclosure forms show that Bondi sold between $1 million and $5 million worth of shares on April 2. That day, after the market closed, Trump’s “Liberation Day” press conference sent the market tumbling.
A Study of Mint Plants. A Device to Stop Bleeding. This Is the Scientific Research Ted Cruz Calls “Woke.”
The senator flagged thousands of National Science Foundation grants for using words like “female” and “diversify.” A ProPublica analysis found numerous examples of projects caught up in his crude method for identifying research he calls “woke.”